Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senate Committee Moves Bipartisan FDA Reform Bill Toward Floor

This article was originally published in The Gray Sheet

Executive Summary

Legislation was reported out of committee last week, with some additional amendments under consideration as the user fee reauthorization bill moves closer to the Senate floor. House members still struggle to reach consensus.

You may also be interested in...



House Committees Set Key Subpanel Assignments For 113th Congress

Two House committees important to the device industry – Ways & Means and Energy & Commerce – have organized for the 2013-2014 sessions.

House Passes Compromise User Fee Bill; Senate To Vote This Week

The final bill includes device user fee reauthorization and additional FDA reforms, including a streamlined device reclassification process that has some in the device industry nervous.

FDA User Fee Reauthorization Charges Along With Senate Passage

FDA user fee and reform bill sails through Senate on 96-1 vote. House plans to take up its similar legislation this week.

Related Content

Topics

UsernamePublicRestriction

Register

OM016204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel